Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Cash from Investing Activities came in at -$134000.0 in Q4 2025, up 53.63% YoY from -$87220.7 in Q4 2024, and down 1.52% on a QoQ basis from -$132000.0 in Q3 2025.
Keros Therapeutics (KROS) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Cash from Investing Activities data on file, last reported at -$134000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 53.63% year-over-year to -$134000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 million (up 19.68% YoY) and the FY2025 annual result came in at -$1.6 million, up 19.68% from the prior year.
- Cash from Investing Activities slipped to -$134000.0 in Q4 2025, from -$132000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$132000.0 in Q3 2025 to a low of -$1.1 million in Q1 2023.
- A 5-year average of -$410550.0 and a median of -$331000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 1721.43% — and 2025, when it surged 65.8%.
- Tracing KROS's Cash from Investing Activities over 5 years: stood at -$159000.0 in 2021, then plunged by 120.75% to -$351000.0 in 2022, then slumped by 54.13% to -$541000.0 in 2023, then surged by 46.58% to -$289000.0 in 2024, then soared by 53.63% to -$134000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$134000.0 (Q4 2025), -$132000.0 (Q3 2025), and -$720000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -134,000.00 |
| Dec 31, 2025 | -134,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Jun 30, 2025 | -720,000.00 |
| Jun 30, 2025 | -720,000.00 |
| Mar 31, 2025 | -565,000.00 |
| Mar 31, 2025 | -565,000.00 |
| Dec 31, 2024 | -289,000.00 |
| Dec 31, 2024 | -289,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Jun 30, 2024 | -310,000.00 |
| Jun 30, 2024 | -310,000.00 |
| Mar 31, 2024 | -946,000.00 |
| Mar 31, 2024 | -946,000.00 |
| Dec 31, 2023 | -541,000.00 |
| Dec 31, 2023 | -541,000.00 |
| Sep 30, 2023 | -550,000.00 |
| Sep 30, 2023 | -550,000.00 |